Search | Clinical Trials Finder

Conditions: Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm, Post-Transplant Lymphoproliferative Disorder
Interventions: Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine, QS21; Procedure · Drug · Biological
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: B Cell Lymphoma, Follicular Lymphoma, Neoplasm
Interventions: Id-KLH Vaccine, QS-21 (Stimulation-QS-21) Drug; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Herpes Simplex Type 2
Interventions: HerpV and QS-21, Placebo; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Portland, Oregon • Houston, Texas • Seattle, Washington

Conditions: Neuroblastoma
Interventions: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH, oral β-glucan; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza Prevention, Seasonal Influenza
Interventions: VRC-FLUMOS0116-00-VP, ALFQ; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 3
States / cities: Birmingham, Alabama • Rochester, New York • Seattle, Washington

Conditions: Breast Cancer
Interventions: GM2-KLH vaccine, QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: BG505 SOSIP.664 gp140, Placebo, 3M-052-AF, CpG 1018, GLA-LSQ, Alum (Aluminum Hydroxide Suspension), Trimer 4571; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 10
States / cities: Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more

Conditions: Randomised Clinical Trial, Double Blind, Dengue, Challenge Test, Dose Escalation and Safety
Interventions: VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant, ALFQ adjuvant + Saline, rDEN3Delta30; Biological
Lead sponsor: VLP Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: QS21, TF(c)-KLH conjugate vaccine, Thomsen-Friedenreich antigen, keyhole limpet hemocyanin; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: MUC-2-KLH; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: MN rgp120/HIV-1 and A244 rgp120/HIV-1, QS-21, rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2000
U.S. locations: 4
States / cities: Baltimore, Maryland • Rochester, New York • Nashville, Tennessee + 1 more

Conditions: Campylobacter Infection
Interventions: ALFQ, CJCV2; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Prostate, Cancer
Interventions: QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: MUC-2-KLH vaccine, QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Neuroblastoma, High-risk Neuroblastoma, Metastatic Neuroblastoma
Interventions: OPT-821 (QS-21), oral β-glucan; Biological · Dietary Supplement
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Alzheimer's Disease
Interventions: ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg, Placebo- Phosphate buffered saline (PBS); Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 40
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 17 more

Conditions: Breast Cancer
Interventions: Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine, QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer's Disease
Interventions: ACC-001 (vanutide cridificar); Biological
Lead sponsor: JANSSEN Alzheimer Immunotherapy Research & Development, LLC; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Sun City, Arizona • La Jolla, California • Long Beach, California + 20 more

Conditions: Breast Cancer
Interventions: MUC1-KLH vaccine/QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Aluminum hydroxide, QS-21, rgp120/HIV-1MN; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1995
U.S. locations: 4
States / cities: St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 1 more

Conditions: Alzheimer Disease
Interventions: ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 27
States / cities: Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 11 more

Conditions: Solid Tumor, Adult
Interventions: ASV® AGEN2017 + QS-21 Stimulon® adjuvant; Biological
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: QS21, sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine, immunoenzyme technique, immunologic technique, laboratory biomarker analysis; Biological · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease

Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

Safety and Immunogenicity of CJCV2 With and Without ALFQ

Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease

Vaccine Therapy in Treating Patients With Breast Cancer

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Phase 1a Study to Evaluate Immunogenicity of ASV®

Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer